Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,General Medicine
Link
http://link.springer.com/article/10.1007/s11934-018-0835-7/fulltext.html
Reference27 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
2. •• Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46. The CHAARTED trial looked at a total of 790 patients with mHSPC randomized to ADT vs ADT + docetaxel without prednisone. This showed a significant improvement in clinical outcomes with the addition of docetaxel. The majority of the benefit, however, was seen in the high volume/high risk patients.
3. •• James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77. This is a multi-arm, multi-stage study run primarily in the UK comparing ADT vs ADT + docetaxel with prednisolone. This helped confirm clinical benefit of the addition of docetaxel to uprfront ADT.
4. •• James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51. This study encompasses additional arms of the STAMPEDE trial comparing ADT vs ADT + abiraterone/prednisone. Clinical benefit was seen with the addition of abiraterone, and this trial included N0M0 patients as well.
5. •• Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60. This is a double blinded, placebo controlled, randomized trial comparing ADT + placebo to ADT + abiraterone/prednisone in metastatic prostate cancer patients (n=1199). It showed clinical benefit of adding abiraterone/prednisone across all subgroups.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Increased expression of CELSR3 indicates a poor prognostic factor for Prostate Cancer;Journal of Cancer;2021
2. Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel;Therapeutic Advances in Medical Oncology;2021-01
3. Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer;Advances in Radiation Oncology;2019-10
4. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review;World Journal of Urology;2019-03-04
5. Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone;Investigational New Drugs;2018-10-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3